Abivax shares jump 36% on positive ulcerative colitis drug trial data

Key facts

• Abivax shares increased by 36%.
• The increase followed the release of positive Phase 3 trial data for obefazimod.
• Obefazimod is an experimental drug for ulcerative colitis.
• The trial data showed clinically meaningful improvements in patients.
• Abivax plans to submit a New Drug Application to the FDA.
• The FDA submission is planned for late 2026.

Abivax, a French biotechnology company, has reported a significant increase in its share value, jumping 36% after announcing positive results from its Phase 3 clinical trial for obefazimod, an experimental drug designed to treat ulcerative colitis. The trial data indicates that obefazimod has achieved clinically meaningful improvements in patients suffering from the condition. Based on these promising outcomes, Abivax is proceeding with its regulatory pathway and is on schedule to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The company anticipates submitting this application in late 2026. This development marks a crucial step forward for Abivax in its efforts to bring a new treatment option to market for individuals with ulcerative colitis.